196 related articles for article (PubMed ID: 36254099)
1. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Ellervik C; Larsen MK; Kjaer L; Skov V; Hasselbalch HC; Ottesen JT
Cancer Med; 2023 Feb; 12(4):4218-4226. PubMed ID: 36254099
[TBL] [Abstract][Full Text] [Related]
2. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
4. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
5. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Mascarenhas J; Kosiorek HE; Prchal JT; Rambaldi A; Berenzon D; Yacoub A; Harrison CN; McMullin MF; Vannucchi AM; Ewing J; O'Connell CL; Kiladjian JJ; Mead AJ; Winton EF; Leibowitz DS; De Stefano V; Arcasoy MO; Kessler CM; Catchatourian R; Rondelli D; Silver RT; Bacigalupo A; Nagler A; Kremyanskaya M; Levine MF; Arango Ossa JE; McGovern E; Sandy L; Salama ME; Najfeld V; Tripodi J; Farnoud N; Penson AV; Weinberg RS; Price L; Goldberg JD; Barbui T; Marchioli R; Tognoni G; Rampal RK; Mesa RA; Dueck AC; Hoffman R
Blood; 2022 May; 139(19):2931-2941. PubMed ID: 35007321
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
8. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
9. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
12. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
Wang R; Shallis RM; Stempel JM; Huntington SF; Zeidan AM; Gore SD; Ma X; Podoltsev NA
Blood Adv; 2023 Mar; 7(5):734-743. PubMed ID: 35917456
[TBL] [Abstract][Full Text] [Related]
13. ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis.
Buks R; Brusson M; Cochet S; Galochkina T; Cassinat B; Nemazanyy I; Peyrard T; Kiladjian JJ; de Brevern AG; Azouzi S; El Nemer W
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805426
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
15. The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.
Skov V; Riley CH; Thomassen M; Kjær L; Stauffer Larsen T; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2017 Aug; 58(8):1914-1921. PubMed ID: 27911124
[TBL] [Abstract][Full Text] [Related]
16. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
[TBL] [Abstract][Full Text] [Related]
17. IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.
Huang X; Ma T; Zhu Y; Jiao B; Yu S; Wang K; Mi JQ; Ren R
Front Med; 2022 Jun; 16(3):403-415. PubMed ID: 34331664
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Quintás-Cardama A; Kantarjian HM; Giles F; Verstovsek S
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):409-16. PubMed ID: 16810616
[TBL] [Abstract][Full Text] [Related]
19. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
Ahn IE; Natelson E; Rice L
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S300-4. PubMed ID: 24290215
[TBL] [Abstract][Full Text] [Related]
20. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
